title: Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: María J
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: José L
authors.initials: JL
authors.lastname: Casado
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Rodríguez-Sagrado
authors.forename: María L
authors.initials: ML
authors.lastname: Mateos
authors.forename: Carlos
authors.initials: C
authors.lastname: Blesa
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a